

United States of America

Tuberculosis profile

Population 2015

322 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.59 (0.58–0.59)	0.18 (0.18–0.18)
Mortality (HIV+TB only)	0.077 (<0.01–0.38)	0.02 (0–0.12)
Incidence (includes HIV+TB)	10 (8.9–12)	3.2 (2.8–3.7)
Incidence (HIV+TB only)	0.58 (0.49–0.67)	0.18 (0.15–0.21)
Incidence (MDR/RR-TB)**	0.18 (0.14–0.23)	0.06 (0.04–0.07)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.37 (0.2–0.53)	3.9 (2.8–4.9)	4.2 (3–5.5)
Males	0.35 (0.23–0.48)	5.8 (4.6–7.1)	6.2 (4.8–7.6)
Total	0.72 (0.51–0.93)	9.7 (8.8–11)	10 (8.9–12)

TB case notifications, 2015

Total cases notified	9 551
Total new and relapse	9 058
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	93%
- % pulmonary	79%
- % bacteriologically confirmed among pulmonary	83%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.06 (0.04–0.09)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	465	6%
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			130 (110–160)
Estimated % of TB cases with MDR/RR-TB	1.5% (1.2–1.8)	5.5% (3.2–8.8)	
% notified tested for rifampicin resistance	76%	65%	7 227
MDR/RR-TB cases tested for resistance to second-line drugs			82
Laboratory-confirmed cases		MDR/RR-TB: 109, XDR-TB: 1	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	85%	8 237
Previously treated cases, excluding relapse, registered in 2014	79%	397
HIV-positive TB cases, all types, registered in 2014	80%	467
MDR/RR-TB cases started on second-line treatment in 2013	79%	39
XDR-TB cases started on second-line treatment in 2013	100%	1

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2016

National TB budget (US\$ millions)	142
------------------------------------	-----


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB